Patented formulation said to improve body absorption of CBD and other cannabinoids
Harvest One Cannabis Inc. reports the company's wholly owned subsidiary, Satipharm Ltd., has launched European sales of its recently reformulated CBD capsules.
"The first product to market is the Satipharm 10 mg CBD Gelpell® capsule that provides superior bioavailability and quality," notes a press release from Harvest One, a global cannabis company that develops and provides lifestyle and wellness products to consumers and patients in regulated markets around the world. They are currently available online at www.satipharm.com.
Bricks and mortar distribution of capsules "will follow with major retailers throughout the United Kingdom and the European Union, with Canadian distribution to follow," the company statement reports.
Satipharm points out that its technology "improves the body's absorption of CBD and other cannabinoids through a patentable formulation of CBD hemp extract contained in seamless Gelpell® gelatine biospheres." The biospheres "are placed in gastro-resistant capsules, ensuring the timely release of CBD in the small intestine, thereby improving bioavailability, and further ensuring that patients receive a consistent dose of CBD, "it adds.
"We are delighted with the launch of Satipharm's new website and e-commerce platform," making the capsules available to consumers across Europe, comments company president Jonathan Hartshorn.
"The launch of Satipharm's patented CBD Gelpell® formulated capsules is an integral part of Harvest One's health and wellness strategy," adds Grant Froese, CEO of Harvest One. "We look forward to launching additional product lines as we advance our health and wellness strategy in regulated markets around the world," Foese says.
Want to keep up to date on what's happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.